FFA
URGN icon

Farther Finance Advisors’s UroGen Pharma URGN Stock Holding History

Farther Finance Advisors’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$3.33K Buy
82
+58
+242% +$2.49K ﹤0.01% 5198
2026
Q2 		$883 Hold
24
– – ﹤0.01% 5406
2026
Q1 		$455 Sell
24
-232
-91% -$4.65K ﹤0.01% 5290
2025
Q4 		$6K Buy
256
+211
+469% +$4.58K ﹤0.01% 4203
2025
Q3 		$898 Buy
45
+44
+4,400% +$790 ﹤0.01% 4397
2025
Q2 		$14 Hold
1
– – ﹤0.01% 4445
2025
Q1 		$11 Sell
1
-11
-92% -$117 ﹤0.01% 4218
2024
Q4 		$128 Hold
12
– – ﹤0.01% 3747
2024
Q3 		$152 Buy
12
+6
+100% +$89 ﹤0.01% 3707
2024
Q2 		$99 Hold
6
– – ﹤0.01% 3600
2024
Q1 		$85 Hold
6
– – ﹤0.01% 3405
2023
Q4 		$90 Buy
+6
New +$78 ﹤0.01% 3316

Other funds holding URGN

HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
BIAS
Beacon Investment Advisory Services Morristown, New Jersey $2.66B AUM 29.77% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

Farther Finance Advisors's URGN Position: Q3 2026 in Review

Farther Finance Advisors increased its UroGen Pharma (URGN) stake by 242% in Q3 2026, buying an estimated $2.49K and bringing the position to 82 shares worth $3.33K. The position accounts for ﹤0.01% of the portfolio, ranked #5198.

Farther Finance Advisors first reported a position in URGN in Q4 2023 and has held it in 12 quarters since. The position peaked at $6K in Q4 2025. 6 funds tracked by Wall St. Rank hold URGN as of Q3 2026.

  • Farther Finance Advisors held 82 shares of UroGen Pharma worth $3.33K as of Q3 2026.
  • Farther Finance Advisors bought 58 UroGen Pharma shares in Q3 2026, an estimated $2.49K.
  • UroGen Pharma made up ﹤0.01% of Farther Finance Advisors's portfolio in Q3 2026, its #5198 holding.
  • Farther Finance Advisors first reported a position in UroGen Pharma in Q4 2023 and has held it in 12 quarters since.
  • Farther Finance Advisors's UroGen Pharma position peaked at $6K in Q4 2025.
  • 6 funds tracked by Wall St. Rank held UroGen Pharma as of Q3 2026.

Based on Farther Finance Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.